Progress of diagnosis and therapy on gastrointestinal stromal tumors

Abstract

Abstract:

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors originating in the gastrointestinal tract. The understanding of GIST's pathogenesis improves the clinical diagnosis and treatment of this disease. And the diagnosis and treatment of GIST becomes the model of tumor multidisciplinary treatment. This article summarizes the progress of diagnosis and treatment of GIST, including the pathology, surgery and drug therapy. We hope this overview can help clinical doctors to treat GIST patients better.

Key words: GIST, diagnosis, therapy, progress, TKI

CLC Number:

R735

HE Miao, FAN Jing, WANG Ziwei, ZHAO Hezhao. Progress of diagnosis and therapy on gastrointestinal stromal tumors[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(11): 1315-1320.

References

［1］Yan L, Zou L, Zhao W, et al. Clinicopathological significance of c-KIT mutation in gastrointestinal stromal tumors: a systematic review and meta-analysis［J］. Sci Rep, 2015, 5: 13718.
［2］Lin JX, Chen QF, Zheng CH, et al. Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up［J］. J Cancer Res Clin Oncol, 2017, 143(4): 727-734.
［3］Ricci R, Saragoni L. Everything you always wanted to know about GIST (but were afraid to ask) an update on GIST pathology［J］. Pathologica, 2016, 108(3): 90-103.
［4］Oudijk L,Gaal J,Korpershoek E,et al.SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors［J］.Mod Pathol,2013,26(3):456-463.
［5］Yanagimoto Y, Takahashi T, Muguruma K, et al. Re-appraisal of risk classifications for primary gastrointestinal stromal tumors (GISTs) after complete resection: indications for adjuvant therapy［J］. Gastric Cancer, 2015, 18(2): 426-433.
［6］Ignee A, Jenssen C, Hocke M, et al. Contrast-enhanced(endoscopic) ultrasound and endoscopic ultrasound elastography in gastrointestinal stromal tumors［J］. Endosc Ultrasound, 2017, 6(1): 55-60.
［7］Nakano A, Nakamura M, Watanabe O, et al. Endoscopic characteristics, risk grade, and prognostic prediction in gastrointestinal stromal tumors of the small bowel［J］. Digestion, 2017, 95(2): 122-131.
［8］An HJ, Ryu MH, Ryoo BY, et al. The effects of surgical cytoreduction prior to imatinib therapy on the prognosis of patients with advanced GIST［J］. Ann Surg Oncol, 2013, 20(13): 4212-4218.
［9］Milone M, Elmore U, Musella M, et al. Safety and efficacy of laparoscopic wedge gastrectomy for large gastrointestinal stromal tumors［J］. Eur J Surg Oncol, 2017, 43(4): 796-800.
［10］Zhi X, Jiang B, Yu J, et al. Prognostic role of microscopically positive margins for primary gastrointestinal stromal tumors: a systematic review and meta-analysis［J］. Sci Rep, 2016, 6: 21541
［11］Kubo N, Takeuchi N. Gastrointestinal stromal tumor of the stomach with axillary lymph node metastasis: a case report［J］. World J Gastroenterol, 2017, 23(9): 1720-1724.
［12］Pelletier JS, Gill RS, Gazala S, et al. A systematic review and meta-analysis of open vs. laparoscopic resection of gastric gastrointestinal stromal tumors［J］. J Clin Med Res, 2015, 7(5): 289-296.
［13］Joensuu H, Reichardt P, Eriksson M, et al. Gastrointestinal stromal tumor: a method for optimizing the timing of CT scans in the follow-up of cancer patients［J］. Radiology, 2014, 271(1): 96-103.
［14］Du CY, Zhou Y, Song C, et al. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China［J］. Eur J Cancer, 2014, 50(10): 1772-1778.
［15］Park SJ, Ryu MH, Ryoo BY, et al. The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses［J］. Ann Surg Oncol, 2014, 21(13): 4211-4217.
［16］Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial［J］. Lancet, 2009, 373(9669): 1097-1104.
［17］Li J, Gong JF, Wu AW, et al. Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor ［J］. Eur J Surg Oncol, 2011, 37(4): 319-324.
［18］Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial［J］. JAMA, 2012, 307(12): 1265-1272.
［19］Fu Y, Hao H, Guo L, et al. Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor［J］. Oncotarget, 2017, 8(6): 10136-10144.
［20］Rossi S, Congedo T, Ricci R, et al. Is surgery mandatory in locally advanced gastrointestinal stromal tumors after imatinib? A case report and literature review［J］. J gastrointest Oncol, 2017, 8(1): E4-9.
［21］Le Cesne A, Ray-Coquard I, Bui BN, et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial［J］. Lancet Oncol, 2010, 11(10): 942-949.
［22］Tirumani SH, Baheti AD, Tirumani H, et al. Update on gastrointestinal stromal tumors for radiologists［J］. Korean J Radiol, 2017, 18(1): 84-93.
［23］Sym SJ, Ryu MH, Lee JL, et al. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs)［J］. J Surg Oncol, 2008, 98(1): 27-33.
［24］Yoo C, Ryu MH, Ryoo BY, et al. Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800mg/day in patients with advanced gastrointestinal stromal tumors［J］. Invest New Drugs, 2013, 31(5): 1367-1374.
［25］Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial［J］. Lancet, 2006, 368(9544): 1329-1338.
［26］Li J, Gao J, Hong J, Shen L. Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors［J］. Future Oncol, 2012, 8(5): 617-624.
［27］Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial［J］. Lancet, 2013, 381(9863): 295-302.
［28］Kang YK, Ryu MH, Yoo C, et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial［J］. Lancet Oncol, 2013, 14(12): 1175-1182.
［29］Demetri GD, Wang Y, Wehrle E, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors［J］. J Clin oncol, 2009,27(19):3141-3147.
［30］Hompland I, Bruland YS, Ubhayasekhera K, et al. Clinical implications of repeated drug monitoring of imatinib in patients with metastatic gastrointestinal stromal tumour［J］. Clin Sarcoma Res, 2016,6:21.
［31］Xu H,Ma L,Xu W,et al.A Chinese multi-center study on the significance of monitoring imatinib plasma concentration in patients with gastrointestinal stromal tumor before and after administration［J］.Zhonghua Wei Chang Wai Ke Za Zhi,2016,19(11):1271-1276.
［32］Yoo C, Ryu MH, Kang BW,et al. Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors:impact of gastrointestinal resection on exposure to imatinib［J］. J Clin Oncol, 2010, 28(9):1554-1559.

[1]	WANG Ruyue, XIE Fei, WANG Xin, LI Hongyu. Therapeutic effect of lienal polypeptide injection on bone marrow suppression and immunodeficiency in KM mice following chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1000-1007.
[2]	HE Lihua, ZHU Xiuzhi, JIANG Yizhou. Research progress on immunotherapy for triple-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853.
[3]	ZHANG Huyunlong, ZHU Xiuzhi, JIN Xi, SHAO Zhimin. Mechanisms of endocrine-resistance and therapeutic breakthroughs in hormone receptor-positive, HER2-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 854-865.
[4]	LUO Shiping, ZHANG Jie, YU Yushuai, SONG Chuangui. Advances in targeted therapy for HER2-positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 876-886.
[5]	XIANG Yimei, ZHANG Ningning, HUANG Yuxin, ZENG Xiaohua. Research progress of biomarkers related to the efficacy of HER2 positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 887-897.
[6]	WANG Chaoyi, SONG Qiang, XIONG Xin, WANG Mengyuan. Research progress on diagnosis and treatment of granulomatous lobular mastitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 910-917.
[7]	HOU Qiong, LIU Fei, CHEN Chuanrong. Immunotherapy combined with anti-angiogenic drugs and chemotherapy in negative driver gene and advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 775-779.
[8]	YU Qiaoling, ZHAI Weiwei, LIU Ping, QIU Bo, WU Huizhen. Research progress in plasma concentration monitoring of rivaroxaban [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 809-817.
[9]	LI Qinghua, ZHAO Yan, ZHAO Haigang, GAO Pengfei, XU Bingxin. Value of ABCB1 G2677T gene polymorphism detection in lipid-lowering therapy with atorvastatin in patients suffered from ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 633-640.
[10]	QIAO Hongliang, DING Ning, DENG Kaihong, LIU Binbin, DONG Chuanjiang, CHEN Xiaobo, ZOU Lili. New progress in research on novel control strategies for methicillin-resistant staphylococcus aureus infection [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 676-687.
[11]	CHEN Manxin, ZHANG Bingyu, DAI Min. Clinical efficacy of intracoronally targeted recombinant human urokinase combined with percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI) with high thrombus burden [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 544-549.
[12]	LI Shuang, HAN Shuzhen, DAI Yuting, XIU Minghui, DU Xianqin, HE Jianzheng, LIN Xingyao. Progress in the prevention and treatment of traditional Chinese medicine based on the mechanism of intestinal injury of various chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 583-593.
[13]	TAO Yijia, YANG Chun, LIU Cunming . Progress in clinical application of topical anesthesia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 594-600.
[14]	LI Mengxue, HE Jie, YU Xiaxia, HU Linlin, SHAO Hua. Research progress in population pharmacokinetics of rituximab [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 468-474.
[15]	ZHANG Qiang, ZHENG Huajun, LI Quan. Research progress on the treatment of autism spectrum disorders based on gut microbiota intervention [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 475-480.